Lotus Tissue Repair

Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

[Read More]